2023 | 2022 FDA Drug Approvals | US Pharma News | iPharmaCenter

Eisai's Leqembi received FDA approval for Alzheimer's | CMS coverage of Leqembi | ipharmacenter

US FDA Withdrawals | News | Blenrep was withdrawn from the US market | iPharmaCenter

COVID19 drug updates | FDA EMA approved COVID19 drugs

CMS | Medicare | Medicaid | US Healthcare | News | Blogs | Updates | iPharmaCenter

US FDA approved BMS Sotyktu (deucravacitinib) for moderate to severe plaque psoriasis |iPharmaCenter

Genzyme's Xenpozyme approved for Acid Sphingomyelinase Deficiency | iPharmaCenter

bluebird bio's $2.8 million gene therapy Zynteglo received FDA nod for beta-thalassemia

BMS' Breyanzi was approved for relapsed or refractory LBCL | News | FDA | iPharmacenter

Lilly's and Incyte's Olumiant approved for adults with severe alopecia areata

FDA approved two Opdivo based regimens as a 1L treatment for ESCC | FDA News | iPharmaCenter

FDA approved Kymriah for follicular lymphoma | Novartis | News | Cancer | | Updates | iPharmaCenter

CMS News | HHS | USA | Medicare, and Medicaid | Health insurance | Healthcare News

FDA gave the nod to Pfizer's Paxlovid | Pfizer to supply 2.5 million doses of Paxlovid to the UK

~$10 bn acquisition paying off for Novartis as FDA approved Novartis' Leqvio

Myasthenia Gravis News | FDA and EMA approvals |

American College of Rheumatology (ACR) Convergence all-virtual annual meeting Updates

Despite facing criticism on handling the COVID19 situation, Tedros to continue as WHO chief

FDA approved Novartis Scembli for chronic myeloid leukemia